Last $62.24 USD
Change Today +0.13 / 0.21%
Volume 1.3M
DGX On Other Exchanges
Symbol
Exchange
New York
Stuttgart
As of 8:04 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3 Giralda Farms

Madison, NJ 07940

United States

Phone: 973-520-2700

Fax:

identify women at high risk of breast cancer. Infectious Disease and Immunology: The company launched an HIV 4th generation test that follows the new proposed CDC HIV testing algorithm. It also introduced Hepatitis C Antibody w/Reflex to Quant, which offers healthcare providers a test for HCV screening and confirmation of infection. The company developed and introduced AccuType Ribivarin (ITPA) to assess risk for acquiring ribivarin-induced anemia in patients being treated for HCV infection. This assay helps establish frequency of monitoring in ribivarin-treated patients. In addition, the company developed and introduced Hepatitis C Viral RNA NS3 Genotype. This assay might be used to detect boceprevir and telaprevir resistance-associated NS3 mutations in NS3 protease inhibitor treatment-experienced patients. It licensed and introduced a novel proprietary biomarker for the diagnosis of rheumatoid arthritis sold under the trade name IdentaRA with 14-3-3ç. The company introduced the ImmunoCAP Peanut Component Allergen test, which helps to assess a patient's level of risk of a life-threatening reaction. Cardiovascular and Metabolic Disease: The company released CardioIQ, an advanced cardiovascular risk assessment and enhanced interpretive report. It also released the CardioIQ Ion Mobility test, a proprietary approach to measure lipoprotein subfractions. The company validated and released Presage ST2, approved by the FDA to assess the prognosis of patients associated with heart failure. It developed and released holistic diagnostics solutions for monitoring diabetes and managing renal disease in diabetes. In addition, the company advanced its program in diabetes testing by releasing insulin testing by mass spectrometry, which helps address variability issues that have hindered the clinical use of testing for this analyte. Neurology: The company launched a blood test panel in accordance with professional clinical guidelines to identify treatable causes of dementia and memory loss. It provided solutions to diagnose hereditary peripheral neuropathies by offering a tiered testing approach to test a set of disease genes by next generation DNA sequencing. The company launched new genetic tests for neuromuscular disorders, including several that provide alternatives to invasive muscle and nerve biopsies. It developed tests for treatable immune-mediated neurological disorders. Women's Health: The company further improved its SureSwab Vaginosis/Vaginitis Plus test by expanding the organisms and sample types in the offering. It introduced access to a new non-invasive cell-free fetal DNA screening test developed by Natera, a major innovator in prenatal genetic testing. The company released FSHD testing by DNA combing, the first commercial application of DNA combing technology in the U.S. Prescription Drug Monitoring and Toxicology: The company added various new tests, including testing for synthetic cannabinoids, synthetic stimulants, zolpidem, and other prescription drugs. It expanded its genetic testing services that assist physicians in their treatment of patients with chronic pain. DIAGNOSTIC SOLUTIONS This business group offers various solutions for insurers, healthcare providers, and others. The company provides risk assessment services for the life insurance industry. It also provides testing for clinical trials. In addition, it offers healthcare organizations and clinicians information technology solutions and diagnostic products, including test kits. Clinical Trials Testing The company provides central laboratory testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It develops pharmacogenetic and pharmacogenomic tests to help speed drug approval processes for its clinical trials customers, and capitalizing on the trend to personalized medicine, to focus patient therapy based on a patient's genetic markers. The company has clinical trials testing centers in the United States, the United Kingdom, and India. It provides clinical trials testing in Argentina, Brazil, China, and Singapore through affiliated laboratories. The company serves a ra

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $62.24 USD +0.13

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $88.98 USD +1.64
Hologic Inc $25.53 USD -0.35
Laboratory Corp of America Holdings $105.38 USD -0.34
Myriad Genetics Inc $37.05 USD +0.94
QIAGEN NV €18.61 EUR -0.025
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 11.7x
Price/Sales 1.2x
Price/Book 2.2x
Price/Cash Flow 10.3x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.